Facilitated By

San Antonio Medical Foundation

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating The Efficacy And Safety Of Filgotinib In The Treatment Of Perianal Fistulizing Crohn’s Disease

Brooke Army Medical Center

Brooke Army Medical Center (BAMC) at Fort Sam Houston, Texas, is proud to provide safe, quality care to our military service members, their families, veterans and civilian emergency patients as the most robust and productive healthcare organization within the Military Health System (MHS).

Principal Investigator(s)
Email for information
Collaborating Institutions
Geneva
Research Start Date
Status
Active

This is a phase 2, double-blind, randomized, placebo-controlled study evaluating the efficacy and safety of filgotinib in the treatment of perianal fistulizing Crohn’s Disease (CD). Approximately 75 subjects aged 18 to 75 years with perianal fistulizing CD will be randomized to 1 of 3 treatment groups in a 2:2:1 ratio

Collaborative Project
Clinical Care
Infectious Disease
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.